Haddad Robert, Colevas A Dimitrios, Krane Jeffrey F, Cooper Dennis, Glisson Bonnie, Amrein Philip C, Weeks Linda, Costello Rosemary, Posner Marshall
Dana Farber Cancer Institute, Department of Adult Oncology, SW430G, 44 Binney Street, Boston, MA 02115, USA.
Oral Oncol. 2003 Oct;39(7):724-7. doi: 10.1016/s1368-8375(03)00097-6.
Phase II study of Herceptin (Trastuzumab) in patients with advanced salivary gland tumors overexpressing Her2/neu. Patients with advanced, incurable salivary gland tumors and 2(+) or 3(+) Her2/neu expression in their tumors were enrolled in the study. After an initial dose of 4 mg/kg, patients received 2 mg/kg weekly. Patients were treated until they experienced progression of disease or unacceptable toxicity. The study was closed early when it has become clear that the majority of tumors screened did not overexpress Her2/neu. Fourteen patients were enrolled in the study. A total of 86 cycles of Herceptin were delivered with a median of three cycles per patient (range 1-40). Median time to progression was 4.2 months. One patient with metastatic mucoepidermoid carcinoma has received 40 cycles of Herceptin to date with a documented partial response. Herceptin given as a single agent has a low activity in salivary gland tumors overexpressing Her2/neu. New agents are still needed.
赫赛汀（曲妥珠单抗）用于治疗过表达Her2/neu的晚期涎腺肿瘤患者的II期研究。患有晚期、无法治愈的涎腺肿瘤且肿瘤中Her2/neu表达为2(+)或3(+)的患者被纳入该研究。初始剂量为4mg/kg后，患者每周接受2mg/kg的治疗。患者接受治疗直至出现疾病进展或不可接受的毒性。当明确大多数筛查的肿瘤未过表达Her2/neu时，该研究提前结束。14名患者被纳入该研究。共进行了86个周期的赫赛汀治疗，每位患者的中位数为3个周期（范围1 - 40）。疾病进展的中位时间为4.2个月。一名转移性黏液表皮样癌患者迄今已接受40个周期的赫赛汀治疗，有记录显示部分缓解。作为单一药物使用时，赫赛汀在过表达Her2/neu的涎腺肿瘤中活性较低。仍需要新的药物。
